Updates and Statements

02.02.2024

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

01.26.2024

Pfizer Receives Positive CHMP Opinion for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Candidate for Infants and Children

12.21.2023

Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP ABBOJECT® Syringe; 8.4% Sodium Bicarbonate Injection, USP Lifeshield® ABBOJECT® Syringe; and Atropine Sulfate Injection, USP Lifeshield® ABBOJECT® Syringe

12.21.2023

Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial Due To The Potential For Presence of Glass Particulate Matter

12.15.2023

Pfizer Receives Positive CHMP Opinion for Ulcerative Colitis Treatment

11.13.2023

Pfizer’s TALZENNA® in Combination with XTANDI® Receives CHMP Positive Opinion in the European Union for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

10.25.2023

Pfizer’s PENBRAYA™ Receives Recommendation for Prevention of Meningococcal Disease in Adolescents and Young Adults from Advisory Committee on Immunization Practices

10.13.2023

Pfizer’s ELREXFIO™ Receives Positive CHMP Opinion for Relapsed and Refractory Multiple Myeloma

10.05.2023

FDA Grants Interchangeable Designation to Pfizer’s Biosimilar ABRILADA™

10.02.2023

Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP and 1% and 2% Lidocaine HCl Injection, USP Due To The Potential For Presence of Glass Particulate Matter

09.07.2023

Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

07.21.2023

Pfizer Receives Positive CHMP Opinion for Alopecia Areata Treatment